Grants: This research has been supported by grants # RBAU013W3J_010 from FIRB and # 3398 from Ministero della Salute. Clonality status was determined by investigation of X chromosome inactivation patterns (XCIPs). We found a statistically significant positive correlation between high TA and monoclonal pattern of XCIP. Therefore our data suggest that the use of multiple tumor markers may contribute to a better understanding of the deregulated physiology of these disorders and provide useful prognostic factors.
Introduction
Telomeres are non-encoding regions of DNA capping the ends of chromosomes, essential for genetic stability and cell replication; 1 Estimation of telomerase activity.
TA was determined in PMN and MNC with the TRAPeze telomerase detection kit (Intergen Co.), based on the original method by Kim et al. 2 For each sample, the following controls were included: a heat-treated negative control, a positive control (HL-60 cell line) 12 and an internal standard, to monitor PCR inhibition and for quantitative analysis of the reaction products. The amount of telomerase product for each reaction was expressed in Total Product Generated units (TPG). The assay has a linear range of 1 to 300 TPG, equivalent to the TA from approximately 30 to 10,000 control cells. Thirty healthy age-matched females were included as controls.
XCIP PCR assay
To assess clonality, we took advantage of a highly polymorphic short tandem repeat For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Analysis of X chromosome inactivation was therefore performed according to Karasawa 16 , with some modifications. Primers sequences were as follows: F, 
Results and Discussion
Thirty-four female patients with PV or ET were tested for heterozygosity at the HUMARA locus and 27 (82%) were found informative. Five of them were excluded from the study due to excess skewing, defined as 90% of the cells with the same X chromosome active. 11 Clonality status was therefore determined in PMN and MNC by XCIP analysis in 22 patients (Table 1) . PMN expressed a monoclonal XCIP in 9 out of 13 subjects with ET (69%), and in 6 out of 9 with PV (67%). MNC were always polyclonal. In patient 10 with ET ( its significance will only be ascertained by a prospective study of clonality and TA on a larger cohort of patients over a long period of follow-up.
Although ET and PV are diseases with a relatively benign course, death due to progression to myelofibrosis and acute leukemia is not a rare event. Therefore, implications for future efforts to treat the subgroup of patients with monoclonal 
